Literature DB >> 205385

Lecithin--cholesterol acyltransferase and the lipoprotein abnormalities of obstructive jaundice.

J Agorastos, C Fox, D S Harry, N McIntyre.   

Abstract

1. We have studied the plasma lipoprotein abnormalities in obstructive jaundice to test the hypothesis that the abnormalities would correlate with plasma lecithin--cholesterol acyltransferase activity. 2. Very-low-density lipoproteins (VLDL) were normal in composition and had a normal pre-beta electrophoretic mobility when lecithin--cholesterol acyltransferase activity was high. When it was low VLDL had abnormal composition and ran in the beta position. 3. With high lecithin--cholesterol acyltransferase activity, low-density lipoprotein (LDL) was normal and cholestatic LDL (LP-X) was not found. With low lecithin--cholesterol acyltransferase activity up to three LDL fractions were found: (i) large triglyceride-rich particles, (ii) LP-X and (iii) a triglyceride-rich cholesteryl ester-poor particle of normal dimensions. 4. High-density lipoprotein (HDL) concentrations correlated with lecithin--cholesterol acyltransferase activity and HDL were normal in composition and electron-microscopic appearance when the activity was high. When lecithin--cholesterol acyltransferase activity was low HDL was abnormal in composition and 'stacked discs' were seen on electron microscopy as well as normal spherical particles. 5. These results suggest that low lecithin-cholesterol acyltransferase activity may cause at least some of the lipoprotein changes of obstructive jaundice.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 205385     DOI: 10.1042/cs0540369

Source DB:  PubMed          Journal:  Clin Sci Mol Med        ISSN: 0301-0538


  8 in total

1.  Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis.

Authors:  M Allocca; A Crosignani; A Gritti; G Ghilardi; D Gobatti; D Caruso; M Zuin; M Podda; P M Battezzati
Journal:  Gut       Date:  2006-04-21       Impact factor: 23.059

2.  Hyperlipidemia in Chronic Cholestatic Liver Disease.

Authors:  Matteo Longo; Andrea Crosignani; Mauro Podda
Journal:  Curr Treat Options Gastroenterol       Date:  2001-04

3.  Lipoprotein pattern and plasma lipoprotein lipase activities in patients with primary biliary cirrhosis. Relationship with increase of HDL2 fraction in Lp-X-positive and Lp-X-negative subjects.

Authors:  G Baldo-Enzi; M R Baiocchi; M Grotto; A R Floreani; M Zagolin; M Chiaramonte; F Cera; R Fellin
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

Review 4.  Familial LCAT deficiency and fish-eye disease.

Authors:  N McIntyre
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

5.  Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis.

Authors:  M Longo; A Crosignani; P M Battezzati; C Squarcia Giussani; P Invernizzi; M Zuin; M Podda
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

6.  Erythrocyte echinocytosis in liver disease. Role of abnormal plasma high density lipoproteins.

Authors:  J S Owen; D J Brown; D S Harry; N McIntyre; G H Beaven; H Isenberg; W B Gratzer
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

7.  Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay.

Authors:  Shimpi Bedi; Erwin Garcia; Elias J Jeyarajah; Irina Shalaurova; Maria Camila Perez-Matos; Z Gordon Jiang; Robin P F Dullaart; Steven P Matyus; William J Kirk; James D Otvos; W Sean Davidson; Margery A Connelly
Journal:  J Clin Med       Date:  2020-09-10       Impact factor: 4.241

8.  Profoundly Disturbed Lipoproteins in Cirrhotic Patients: Role of Lipoprotein-Z, a Hepatotoxic LDL-like Lipoprotein.

Authors:  Eline H van den Berg; Jose L Flores-Guerrero; Eke G Gruppen; Erwin Garcia; Margery A Connelly; Vincent E de Meijer; Stephan J L Bakker; Hans Blokzijl; Robin P F Dullaart
Journal:  J Clin Med       Date:  2022-02-24       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.